Cutaneous melanoma represents a paradigm of immunological complexity, where multifactorial primary and acquired resistance often undermine the clinical efficacy of conventional immune checkpoint blockades and targeted therapies. This review provides a comprehensive analysis of the strategic shift toward precision immuno-oncology, focusing on the mechanistic synergy between personalized neoantigen-directed vaccines and integrated multi-omics profiling. Rather than viewing these as independent pillars, we propose an integrated framework where multi-omics data functions as the indispensable 'operating system' that drives the entire lifecycle of neoantigen vaccines. By targeting patient-specific somatic mutations, bespoke vaccines are capable of orchestrating, high-avidity T-cell responses with superior specificity and minimal off-target toxicity. We evaluate the clinical evolution and immunological foundations of advanced vaccine platforms-including mRNA, synthetic long peptides (SLPs), and engineered exosome-based systems-highlighting their transformative potential in the neoadjuvant and adjuvant settings. Central to this paradigm is the deployment of a robust multi-omics ecosystem (encompassing genomics, transcriptomics, epigenomics, proteomics, and the host microbiome) to decipher the dynamic landscape of the melanoma tumor microenvironment (TME). Facilitated by artificial intelligence (AI) and real-time liquid biopsy monitoring, this framework enables an iterative, biologically informed feedback loop for adaptive clinical management. We emphasize that the integration of personalized vaccines with immune checkpoint inhibitors (ICIs) and MAPK pathway inhibitors is essential to dismantle resistance barriers, providing a definitive roadmap for achieving durable clinical remission and curative outcomes in the era of personalized oncology. de novo
